Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$32 Mln
P/E Ratio
--
P/B Ratio
10.04
Industry P/E
--
Debt to Equity
0.37
ROE
-4.65 %
ROCE
-180.35 %
Div. Yield
0 %
Book Value
1.59
EPS
-4.91
CFO
$-19.67 Mln
EBITDA
$-74.95 Mln
Net Profit
$-83.67 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Coeptis Therapeutics Inc (COEP)
| 79.82 | 5.21 | -16.12 | 29.04 | -63.34 | -- | -- |
|
BSE Sensex
| 5.34 | 9.68 | 8.04 | 13.44 | 15.08 | 21.17 | 11.60 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Coeptis Therapeutics Inc (COEP)
| -64.62 | -48.80 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 20.59 | 4,766.51 | 24.67 | 81.65 | |
| 35.67 | 6,488.23 | -- | -- | |
| 71.09 | 7,447.54 | 61.07 | 20.1 | |
| 9.08 | 10,293.17 | -- | -6.58 |
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are... licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. Read more
Co-Founder, Chairman of the Board, CEO & President
Mr. David Mehalick
Co-Founder, Chairman of the Board, CEO & President
Mr. David Mehalick
Headquarters
Wexford, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Coeptis Therapeutics Inc (COEP) stood at $ 9 Mln as on 31-Dec-24
The share price of Coeptis Therapeutics Inc (COEP) is $9.89 (NASDAQ) as of 12-May-2025 12:07 EDT. Coeptis Therapeutics Inc (COEP) has given a return of -63.34% in the last 3 years.
Coeptis Therapeutics Inc (COEP) has a market capitalisation of $ 32 Mln as on 09-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Coeptis Therapeutics Inc (COEP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Coeptis Therapeutics Inc (COEP) and enter the required number of quantities and click on buy to purchase the shares of Coeptis Therapeutics Inc (COEP).
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
The CEO & director of Mr. David Mehalick. is Coeptis Therapeutics Inc (COEP), and CFO & Sr. VP is Mr. David Mehalick.
There is no promoter pledging in Coeptis Therapeutics Inc (COEP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,019
|
|
|
772
|
|
|
732
|
|
|
561
|
| Coeptis Therapeutics Inc (COEP) | Ratios |
|---|---|
|
Return on equity(%)
|
-245.69
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Coeptis Therapeutics Inc (COEP) was $0 Mln.
$0.39
(
